This longitudinal study comprising 159 patients with psoriasis and psoriatic arthritis showed apremilast to be an effective and safe therapy for improving skin condition and lower psoriasis severity.

This study examined the real-life outcomes of apremilast in patients with psoriasis (selective phosphodiesterase-4 inhibitor) in routine practice.

One hundred and fifty-nine individuals (90 men) with plaque psoriasis were included. Out of these, 31% of the patients had psoriatic arthritis. At the time of enrollment, all the individuals initiated apremilast. 

During the course of 12 months, noticeable improvement in Dermatology Life Quality Index scores, body surface area, and Psoriasis Area and Severity Index was observed. However, there were no changes in improvement considering the body mass index (BMI). Lack of response led to the withdrawal of apremilast in 10.6% of the patients.

Apremilast is a safe and effective therapy in psoriatic patients, and its outcome is not dependent on the BMI.